From Patterson's 19 June 09 Research Note (page 10):
A study by Czerepak et Ryser established a biotech failure rate of 74% (although we would make the
observation that aspects of the treatment have been significantly de-risked, as a result of the current
widespread use of Artmether in tablet form). This implies a risk adjusted value for Eastland® of $0.26.
If phase III trials are successful and after other appropriate submissions (below uses FDA approvals
as a proxy albeit not relevant for ArtiMistTM), then Eastland® valuation would rise to ~$1.50 on a derisked
commercialised basis.
- Forums
- ASX - By Stock
- EMS
- pre trial npv of 26c
pre trial npv of 26c
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EMS (ASX) to my watchlist
|
|||||
Last
2.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.387M |
Open | High | Low | Value | Volume |
2.1¢ | 2.1¢ | 2.1¢ | $995 | 47.37K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9763 | 2.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.3¢ | 76639 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9763 | 0.021 |
1 | 150000 | 0.020 |
1 | 30000 | 0.019 |
1 | 27833 | 0.018 |
3 | 178091 | 0.017 |
Price($) | Vol. | No. |
---|---|---|
0.023 | 76639 | 1 |
0.025 | 21000 | 1 |
0.026 | 250000 | 1 |
0.027 | 4000 | 1 |
0.031 | 220433 | 1 |
Last trade - 12.05pm 29/08/2024 (20 minute delay) ? |
Featured News
EMS (ASX) Chart |